6 results about "Gliclazide" patented technology

Disclosed in the present application are a method and drug for preventing or treating a neurodegenerative disease, whereby a therapeutically effective amount of gliclazide or a pharmaceutically acceptable salt thereof or a combination of gliclazide or a pharmaceutically acceptable salt thereof and acetaminophen or a pharmaceutically acceptable salt thereof is used or comprised. The method and drug of the present invention can significantly alleviate symptoms such as hyposmia, cognitive dysfunction, and psychiatric symptoms in patients with neurodegenerative diseases that cannot be treated with existing drugs, and can be particularly used for controlling the progression of neurodegenerative diseases.

1. The name of the design product: packing box (gliclazide sustained-release tablet). 2. The use of the design product: packing for gliclazide sustained-release tablet. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo best indicating the design points: front view.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a gliclazide sustained-release tablet and a preparation method thereof.The gliclazide sustained-release tablet takes gliclazide as an active ingredient and is matched with a sustained-release system composed of a specific composite sustained-release framework material, a pore-foaming agent and a sustained-release regulator, and the sustained-release effect of the gliclazide sustained-release tablet is improved. And pharmaceutically acceptable auxiliary materials such as a filling agent, a disintegrating agent, an adhesive and a lubricating agent are used as auxiliary materials. The preparation method comprises the following steps: preparing a stable sustained-release system through a specific process by adopting a wet granulation and tabletting method, and carrying out raw and auxiliary material pretreatment, premixing, wet granulation, particle drying, whole particle total mixing, tabletting and the like to prepare a finished product. Through the synergistic effect of the components of the sustained-release system and the optimized preparation process, the preparation is stable and controllable in drug release, and has no burst release risk; the storage stability is excellent, and the drug release behavior fluctuation is small after long-term storage; meanwhile, the medicine release completeness is good, the bioavailability is high, the requirement for clinical precise treatment of the type 2 diabetes mellitus can be better met, and the defects in the prior art are overcome.

The application provides a preparation process of glipizide, which comprises the following steps: 1) preparing N-nitroso-3-azabicyclo[3.3.0]octane hydrochloride; 2) in the presence of a cerium-based activated carbon catalyst, N-nitroso-3-azabicyclo[3.3.0]octane hydrochloride and hydrazine hydrate are subjected to a reduction reaction in a first organic solvent; after the reaction is completed, filtration is performed, the filtrate is diluted with water, and then extraction, acidification and pH adjustment to 1.5-2.5, low-temperature crystallization, filtration and drying are sequentially performed to obtain N-amino-3-azabicyclo[3.3.0]octane hydrochloride; the cerium-based activated carbon catalyst is prepared by loading a cerium salt on an activated carbon carrier through a precipitation method; and 3) N-amino-3-azabicyclo[3.3.0]octane hydrochloride and p-toluenesulfonylurea are subjected to a heating reflux reaction; after the reaction is completed, post-treatment is performed to obtain glipizide. The whole process does not emit heavy metals, the catalyst can be used repeatedly, and the treatment cost of three wastes is greatly reduced, so that the application provides a green industrialized preparation process chain of glipizide.

The application discloses a drying treatment equipment for gliclazide and a drying method thereof, and belongs to the technical field of drying devices. The drying treatment equipment mainly comprises a rapid drying device and a crushing drying device. The crushing drying device is located at the bottom of the rapid drying device. The rapid drying device comprises a casing. A material distributing mechanism is fixedly connected to the left side of the casing. A collecting hopper is fixedly connected to the bottom rear end of the casing. An air return pipe is fixedly connected to the rear part of the casing. The other end of the air return pipe is fixedly connected to the center of the top of the casing. A rotary drying mechanism is rotatably connected to the inside of the casing. The rotary drying mechanism comprises a rotary air pipe. The gliclazide raw material can be spread as much as possible by the rapid drying device, so that the contact area of the gliclazide raw material with hot air is enlarged, and the rapid drying operation of the gliclazide is realized. The gliclazide raw material which is agglomerated into a group after the rapid drying is crushed by the crushing drying device. The application is mainly used for drying treatment of gliclazide.

The utility model provides a glipizide tablet medicament hopper lifting charging machine, belongs to the technical field of lifting charging machines, and aims to solve the problem that in the operation process of an existing hopper lifting charging machine, unauthorized personnel possibly enter a movement area of a lifting mechanism due to misoperation or negligence, and extremely high safety risks exist. Comprising a base, a connecting plate, a side protection plate, an automatic protection assembly and a height fine adjustment assembly. The connecting plate is rotationally connected in front of the moving plate; the side protection plates are of L-shaped structures, and the two side protection plates are fixedly connected to the left side and the right side of the supporting stand column correspondingly. The two sets of automatic protection assemblies are arranged at the tops of the two side protection plates correspondingly. The height fine adjustment assembly is arranged in front of the moving plate. The front guard plate is driven to be automatically closed and opened through lifting and descending of the hopper, potential safety hazards and operation pain points existing in the hopper lifting feeder for a long time are avoided, installation deviation is eliminated through the height fine adjustment assembly, and the hopper butt joint efficiency and precision are remarkably improved.